Exploring Galleria mellonella larval model to evaluate antibacterial efficacy of Cecropin A (1-7)-Melittin against multi-drug resistant enteroaggregative Escherichia coli. Issue 3 (29th January 2021)
- Record Type:
- Journal Article
- Title:
- Exploring Galleria mellonella larval model to evaluate antibacterial efficacy of Cecropin A (1-7)-Melittin against multi-drug resistant enteroaggregative Escherichia coli. Issue 3 (29th January 2021)
- Main Title:
- Exploring Galleria mellonella larval model to evaluate antibacterial efficacy of Cecropin A (1-7)-Melittin against multi-drug resistant enteroaggregative Escherichia coli
- Authors:
- Vergis, Jess
Malik, S V S
Pathak, Richa
Kumar, Manesh
Kurkure, Nitin V
Barbuddhe, S B
Rawool, Deepak B - Abstract:
- ABSTRACT: High throughput in vivo laboratory models is need for screening and identification of effective therapeutic agents to overcome microbial drug-resistance. This study was undertaken to evaluate in vivo antimicrobial efficacy of short-chain antimicrobial peptide- Cecropin A (1–7)-Melittin (CAMA) against three multi-drug resistant enteroaggregative Escherichia coli (MDR-EAEC) field isolates in a Galleria mellonella larval model. The minimum inhibitory concentration (MIC; 2.0 mg/L) and minimum bactericidal concentration (MBC; 4.0 mg/L) of CAMA were determined by microdilution assay. CAMA was found to be stable at high temperatures, physiological concentration of cationic salts and proteases; safe with sheep erythrocytes, secondary cell lines and commensal lactobacilli at lower MICs; and exhibited membrane permeabilization. In vitro time-kill assay revealed concentration- and time-dependent clearance of MDR-EAEC in CAMA-treated groups at 30 min. CAMA- treated G. mellonella larvae exhibited an increased survival rate, reduced MDR-EAEC counts, immunomodulatory effect and proved non-toxic which concurred with histopathological findings. CAMA exhibited either an equal or better efficacy than the tested antibiotic control, meropenem. This study highlights the possibility of G. mellonella larvae as an excellent in vivo model for investigating the host-pathogen interaction, including the efficacy of antimicrobials against MDR-EAEC strains. Abstract : This study was undertakenABSTRACT: High throughput in vivo laboratory models is need for screening and identification of effective therapeutic agents to overcome microbial drug-resistance. This study was undertaken to evaluate in vivo antimicrobial efficacy of short-chain antimicrobial peptide- Cecropin A (1–7)-Melittin (CAMA) against three multi-drug resistant enteroaggregative Escherichia coli (MDR-EAEC) field isolates in a Galleria mellonella larval model. The minimum inhibitory concentration (MIC; 2.0 mg/L) and minimum bactericidal concentration (MBC; 4.0 mg/L) of CAMA were determined by microdilution assay. CAMA was found to be stable at high temperatures, physiological concentration of cationic salts and proteases; safe with sheep erythrocytes, secondary cell lines and commensal lactobacilli at lower MICs; and exhibited membrane permeabilization. In vitro time-kill assay revealed concentration- and time-dependent clearance of MDR-EAEC in CAMA-treated groups at 30 min. CAMA- treated G. mellonella larvae exhibited an increased survival rate, reduced MDR-EAEC counts, immunomodulatory effect and proved non-toxic which concurred with histopathological findings. CAMA exhibited either an equal or better efficacy than the tested antibiotic control, meropenem. This study highlights the possibility of G. mellonella larvae as an excellent in vivo model for investigating the host-pathogen interaction, including the efficacy of antimicrobials against MDR-EAEC strains. Abstract : This study was undertaken to evaluate in vivo antimicrobial efficacy of short-chain antimicrobial hybrid peptide- Cecropin A (1-7)-Melittin against three multi-drug resistant enteroaggregative E. coli field isolates in a G. mellonella larval model. … (more)
- Is Part Of:
- Pathogens and disease. Volume 79:Issue 3(2021)
- Journal:
- Pathogens and disease
- Issue:
- Volume 79:Issue 3(2021)
- Issue Display:
- Volume 79, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 79
- Issue:
- 3
- Issue Sort Value:
- 2021-0079-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-01-29
- Subjects:
- antimicrobial peptide -- Cecropin A (1-7)-Melittin -- enteroaggregative Escherichia coli -- Galleria mellonella -- multi-drug resistance
Medical microbiology -- Periodicals
Pathogenic microorganisms -- Periodicals
Communicable diseases -- Microbiology -- Periodicals
Communicable diseases -- Pathogenesis -- Periodicals
Host-parasite relationships -- Periodicals
Systems biology -- Periodicals
616.904105 - Journal URLs:
- http://femspd.oxfordjournals.org/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1093/femspd/ftab010 ↗
- Languages:
- English
- ISSNs:
- 2049-632X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6412.743530
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16197.xml